White Paper

NSCLC Clinical Trials: History, Trends, and Opportunities

Lung cancer is one of the diseases that will never vanish from the radar of physicians, scientists, and society. However, there have been significant advances in our understanding and treatment of this disease over the past century, particularly for non-small cell lung cancer (NSCLC). In this white paper, we review the primary diagnostic and treatment options used today, the current trends, and their implications on the design and conduct of NSCLC clinical trials.

Based on PSI CRO’s experience with more than 25 Phase 2 and 3 clinical trials in advanced and metastatic NSCLC during the past ten years, we have experience overcoming several major challenges of these studies. To learn more about how we can support your upcoming NSCLC clinical trial, contact us today.

A Guide to the EU Clinical Trial Regulation: How to Ensure Timely Transition for Current Studies

With the European Union’s Clinical Trial Regulation coming into effect on January 31, 2022, we know there are many questions when it comes to what’s changing and what you need to do to comply. That’s why PSI CRO, drawing on our 25 years of experience managing studies across the globe, is sharing our insights in a new white paper.

In A Guide to the EU Clinical Trial Regulation: How to Ensure Timely Transition for Current Studies, you’ll learn:

  • The new elements introduced by the EU CTR
  • The applicability for current studies
  • How to transition your study to the new requirements

Click the image below to start reading or download a copy.